Monoclonal Antibody to Major Histocompatibility Complex Class II DR Alpha (MHCDRa)
| Code | Size | Price |
|---|
| MAC166Si21-20ul | 20ul | £106.00 |
Quantity:
| MAC166Si21-100ul | 100ul | £207.00 |
Quantity:
| MAC166Si21-200ul | 200ul | £282.00 |
Quantity:
| MAC166Si21-1ml | 1ml | £660.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Rhesus Macaque
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
MHCDRa; HLADRa; Major Histocompatibility Complex Class II DR Alpha
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
HLA Class II Histocompatibility Antigen, DR Alpha Chain
Potency (Clone Number):
1:810000 (6-1#)
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-5ug/mL
Immunohistochemistry: 5-30ug/mL
Immunocytochemistry: 5-30ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-30ug/mL
Immunocytochemistry: 5-30ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Major Histocompatibility Complex Class II DR Alpha (MHCDRa) | RPC166Si01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||